Infection-Chronic Disease Link

In "The Infection-Chronic Disease Link Strengthens,"1 there are comments about the utility of Koch's postulates: "The first criterion remains--the microbial culprit must be present. But the requirements to culture microorganisms and demonstrate infectivity may have become obsolete." This would almost seem to go against the scientific method, since it seems to imply that testing one's hypothesis does not require exhaustive attempts at falsification, the fundamental basis of the scientific

Written byTodd Miller
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In "The Infection-Chronic Disease Link Strengthens,"1 there are comments about the utility of Koch's postulates: "The first criterion remains--the microbial culprit must be present. But the requirements to culture microorganisms and demonstrate infectivity may have become obsolete."

This would almost seem to go against the scientific method, since it seems to imply that testing one's hypothesis does not require exhaustive attempts at falsification, the fundamental basis of the scientific method. Why would scientists NOT want to demonstrate infectivity of an agent that they propose is indeed infectious? Koch's postulates have served us very well for over 100 years. Is it that they are really obsolete, or do scientists really need an explanation for their inability to demonstrate infectivity of their hypothetical pathogenic microbes? Are there too many dollars at stake to apply standard, rigorous scientific standards?

I think it is a slippery slope to start dismissing established postulates, which essentially ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies